Jasper Therapeutics Inc (NAS:JSPR)
$ 23.24 0.61 (2.7%) Market Cap: 348.63 Mil Enterprise Value: 249.05 Mil PE Ratio: 0 PB Ratio: 4.16 GF Score: 41/100

Jasper Therapeutics Inc Corporate Update Call Transcript

Jan 31, 2023 / 01:30PM GMT
Release Date Price: $17 (-3.41%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by and welcome to the Jasper Therapeutics' update conference call. (Operator Instructions) At this time, it is now my pleasure to turn the call over to Ron Martell. Please go ahead, Mr. Martell. Mr. Martell, you may begin today's presentation.

Ron Martell
Jasper Therapeutics, Inc. - CEO

Thank you, operator, and good morning, everyone. We apologize for these technical difficulties and thank you for hanging in there. I'm Ronald Martell, the CEO of Jesper therapeutics. We will be making forward-looking statements on today's call. And slide 2 contains our Safe Harbor Statement, which I encourage you to review.

Now turning to slide 3. It's been an exciting start to the year for Jasper Therapeutics. We end with an announcement of positive clinical data for briquilimab in stem cell transplant for sickle cell disease and acute myeloid leukemia. Our announcement of expanding the development of briquilimab in chronic spontaneous urticaria and closing of the public offerings from leading biotech

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot